FDA Releases Draft Guidance on Early Drug Development for Rare Diseases

Summary

The FDA is releasing a draft guidance to help pharmaceutical companies develop more efficient pre-IND meetings for rare diseases, a process that poses unique challenges due to the nature of these diseases.